Scientific Zambon Pharma October 16, 2019 Breath Therapeutics, a Zambon company, announces presentations at upcoming scientific conferences
Institutional Zambon Pharma July 25, 2019 Zambon completes transformational acquisition of Breath Therapeutics
Scientific Zambon Pharma July 11, 2019 Valeo Pharma Announces the Canadian Launch of Onstryv® (Safinamide Tablets) for the Treatment of Parkinson’s Disease
Scientific Zambon Pharma January 15, 2019 Valeo Pharma and Zambon announce the approval of Onstryv® (safinamide) for Canada
Scientific Zambon Pharma December 11, 2018 NON–CYSTIC FIBROSIS BRONCHIECTASIS (NCFB) FDA GRANTS “FAST-TRACK” AND “QIPD” TO ZAMBON FOR COLISTIMETHATE SODIUM POWDER FOR NEBULIZER SOLUTION DELIVERED BYTHE I-NEB AAD SYSTEM.
Scientific Zambon Pharma November 30, 2018 Zambon announces approval and ARTG listing of Safinamide in Australia for treatment of patients with Parkinson’s disease
Institutional Zambon Pharma November 13, 2018 AstraZeneca and Zambon Announce a Strategic Partnership at CIIE
